Results 121 to 130 of about 2,232,804 (291)
PurposeMetastatic neuroendocrine tumors secrete serotonin and other vasoactive substances that are responsible for carcinoid syndrome and carcinoid heart disease.
Rebecca Dobson+15 more
doaj +1 more source
Carcinoid Syndrome and Oat-cell Carcinoma of the Bronchus [PDF]
J. G. Azzopardi, A. R. Bellau
openalex +1 more source
A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was 'In patients with carcinoid syndrome undergoing valve replacement, will a biological valve have acceptable durability?' Altogether, more ...
N. Mabvuure, A. Cumberworth, S. Hindocha
semanticscholar +1 more source
Síndrome carcinóide – caso clínico
Os tumores carcinóides são neoplasias raras, mais frequentemente encontradas no trato gastrointestinal, responsáveis pela produção de mediadores neuroendócrinos.
Renata Silva+3 more
doaj +1 more source
Abnormal forearm vascular responses in the carcinoid syndrome: the role of kinisns and kinin-generating system. [PDF]
D. T. Mason, Kenneth L. Melmon
openalex +1 more source
Carcinoid heart disease – still a challenging diagnosis?
Neuroendocrine tumors (NETs) are rare neoplasms that can occur anywhere in the body. Mostly, they are located in the gastrointestinal tract or lungs. A third of subjects with NETs present carcinoid syndrome (CS) features.
Benchea Laura Cătălina+3 more
doaj +1 more source
Background/Objective: Pulmonary carcinoid tumors are a rare cause of Cushing’s syndrome and usually present with an indolent course. Here, we present a case of rapid onset and severe Cushing’s syndrome due to a typical pulmonary carcinoid tumor.
Karissa Aldrete, MD, Leena Shahla, MD
doaj
Argentaffinoma of Ileum with Carcinoid Syndrome [PDF]
W F W Southwood+2 more
openalex +1 more source
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study [PDF]
Purpose: The aim of this phase II study was to evaluate the tumour response of neuroendocrine tumours to targeted irradiation with the radiolabelled somatostatin analogue 90Y-DOTATOC.
Haldemann, A.+4 more
core